Evidence map›Paper›PMID 41514522›Full record

ReviewCancers2025

AI-Powered Histology for Molecular Profiling in Brain Tumors: Toward Smart Diagnostics from Tissue.

Maki Sakaguchi, Akihiko Yoshizawa, Kenta Masui, Tomoya Sakai, Takashi Komori

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maki SakaguchiDepartment of Diagnostic Pathology, Nara Medical University, Kashihara 634-8521, Japan.
Akihiko YoshizawaDepartment of Diagnostic Pathology, Nara Medical University, Kashihara 634-8521, Japan.
Kenta MasuiDepartment of Integrative Neuroscience, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.ORCID 0000-0002-5824-6690
Tomoya SakaiInstitute of Integrated Science and Technology, Nagasaki University, Nagasaki 852-8521, Japan.
Takashi KomoriDepartment of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo 183-0042, Japan.ORCID 0000-0002-6812-2149

Funding

Japan Society for the Promotion of Science KAKENHI Grant JP23K06487 (KM)
6 · The paper itself

Abstract

The integration of molecular features into histopathological diagnoses has become central to the World Health Organization (WHO) classification of central nervous system (CNS) tumors, improving prognostic accuracy and supporting precision medicine. However, unequal access to molecular testing limits the universal application of integrated diagnosis. To address this, artificial intelligence (AI) models are being developed to predict molecular alterations directly from histological data. In gliomas, deep learning applied to whole-slide images (WSIs) of permanent sections achieves neuropathologist-level accuracy in predicting biomarkers such as IDH mutation and 1p/19q co-deletion, as well as in molecular subtype classification and outcome prediction. Recent advances extend these approaches to intraoperative cryosections, enabling real-time glioma grading, molecular prediction, and label-free tissue analysis using modalities such as stimulated Raman histology and domain-adaptive image translation. Beyond gliomas, AI-powered histology is being explored in other brain tumors, including morphology-based molecular classification of spinal cord ependymomas and intraoperative discrimination of gliomas from primary CNS lymphomas. This review summarizes current progress in AI-assisted molecular profiling prediction of brain tumors from tissue, highlighting opportunities for rapid, accurate, and globally accessible diagnostics. The integration of histology and computational methods holds promise for the development of smart AI-assisted neuro-oncology.

Indexed as

artificial intelligencebrain tumorintraoperative diagnosismolecular classificationmultimodal AIradiopathomicsWorld Health Organization

Identifiers

PMID41514522
PMCPMC12784969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.